Format

Send to

Choose Destination
Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):739-47. doi: 10.1586/17474124.2014.925799. Epub 2014 May 31.

Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.

Author information

1
Translational Genomics Research Institute, Phoenix, AZ, USA.

Abstract

Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer of poor prognosis with a high mortality, particularly in the advanced or metastatic setting. Until 2011 and the Phase III results of FOLFIRINOX, standard treatment options were limited to gemcitabine. Combination therapy had shown either a lack of or very limited improvement versus monotherapy with gemcitabine. With the positive results of the MPACT study in 2013 showing improved survival with nab-paclitaxel plus gemcitabine combination therapy, there are now more options for oncologists to treat patients with advanced pancreatic cancer. This paper will highlight the Phase I/II and Phase III trials of nab-paclitaxel plus gemcitabine along with discussing their biology and further possible development in treating patients with pancreatic cancer.

KEYWORDS:

5-fluorouracil; FOLFIRINOX; gemcitabine; nab-paclitaxel; pancreatic adenocarcinoma; pancreatic cancer

PMID:
24882381
DOI:
10.1586/17474124.2014.925799
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center